Ethereum enters February 2026 under pressure, testing key support near $2,690 after a historically weak January. Analysts are divided on whether seasonal trends or shifting on-chain dynamics will dictate the month's direction.
Argenta Silver Corp. sees its stock decline following the announcement of a new mineral discovery at its El Quevar project in Argentina and the completion of a substantial equity financing, highlighting the complex calculus investors face with junior mining explorers.
Real Matters Inc. (TSE: REAL) kicked off its 2026 fiscal year with robust double-digit revenue growth and a return to profitability, defying typical seasonal headwinds. The company's performance was fueled by market share gains, new client launches, and improved operational efficiency across its U.S. and Canadian segments.
Standex International Corporation reported robust fiscal second-quarter results, with revenue climbing to $221.32 million and net income reaching $2.12 million. The company raised its quarterly dividend by 6.3% and issued an upbeat forecast for the third quarter, reinforcing confidence in its strategic shift toward high-value engineered products.
Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.
Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Altria Group reported adjusted earnings growth and robust shareholder returns for 2025, even as it grapples with a rapidly transforming nicotine market dominated by illicit flavored vapes and intense competition in oral tobacco.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
GSI Technology Inc. reports a 12% year-over-year revenue increase for Q3 2026, driven by defense sector adoption of its Gemini-II APU. While R&D investments pressure margins, the company highlights a strong cash position and expanding applications in smart cities and robotics.
Facing a tough freight environment, Schneider National's leadership outlines a strategy centered on cost discipline, tech investment, and strategic positioning in intermodal and dedicated services to steer toward future profitability.
KeyCorp's latest quarterly results beat expectations, fueled by higher net interest income and a return to full-year profitability. The regional bank also completed a $200 million share buyback and issued $750 million in new debt, while refreshing its board. Analysts suggest these moves fine-tune the bank's strategy rather than radically alter its investment narrative.
PACCAR reports softer fourth-quarter sales and earnings alongside the retirement of a key executive, yet maintains its full-year profit record and commitment to next-generation truck technology, setting the stage for a pivotal 2026.
Cardinal Energy Ltd. has upsized its equity offering to C$95.15 million, with proceeds aimed at debt repayment and accelerating its thermal oil projects, including the Reford 2 SAGD development. The move highlights the company's strategic pivot but raises questions about dividend sustainability and shareholder dilution in a capital-intensive sector.
American Eagle Outfitters is winding down its Quiet Logistics subsidiary, a strategic retreat from the third-party fulfillment business. The move signals a sharper focus on its core Aerie and American Eagle retail brands amid a challenging environment for apparel retailers.
As Insmed prepares to unveil key data for its TPIP program at a major medical congress, fresh analyst coverage highlights the treatment's potential to reshape the company's future. Amidst a volatile stock performance, investors are weighing high-growth prospects against persistent financial risks.
